Effects of long-term rifampicin administration in primary biliary cirrhosis

Bachs, Laura; Parés, Albert; Elena, Montserrat; Piera, Carlos; Rodés, Joan

doi:10.1016/0016-5085(92)90335-v

Cited by 235Liver Diseases and ImmunityDrug Transport and Resistance MechanismsPediatric Hepatobiliary Diseases and Treatments

Effects of long-term rifampicin administration in primary biliary cirrhosis

Open access

Bachs, Laura, Parés, Albert, Elena, Montserrat, Piera, Carlos, Rodés, Joan·1992·Gastroenterology

DOI 10.1016/0016-5085(92)90335-v

Open this paper in CoChat — free account

Abstract

The effects of rifampicin treatment (10 mg.kg-1.day-1) on pruritus and cholestasis were evaluated in 16 patients with primary biliary cirrhosis and pruritus followed up for 2-24 months. Assessment of pruritus severity, liver tests, aminopyrine breath test, and bile acids was done at 2 weeks and every 3 months after the beginning of the study. Two patients (12.5%) were withdrawn after 2 months of treatment because they had hepatitis caused by rifampicin. Four patients were withdrawn after 4 months because of liver transplantation (3 cases) and the development of leg edema associated with administration of rifampicin. The remaining 10 patients received therapy for 14.4 +/- 0.7 months and did not experience side effects. Pruritus improved in all patients and disappeared in 11 patients (79%) after 3 months of treatment. Moreover, all patients followed up for more than 1 year were free of pruritus. The alkaline phosphatase level decreased significantly, and the aminopyrine breath test results increased significantly after 2 weeks of treatment (P less than 0.001) and did not change thereafter. In the 9 patients treated for 15 months, alkaline phosphatase levels decreased to 63% of the basal levels and aminopyrine breath test results increased to 153% of baseline values. Transaminases, gamma-glutamyltransferase, and total bile salt levels decreased significantly after 2 weeks of treatment but returned to baseline after 3 months. No changes in bilirubin and cholesterol levels were observed. It is concluded that long-term rifampicin treatment is effective for relieving pruritus in primary biliary cirrhosis, but liver enzymes should be monitored to detect drug-induced hepatitis.

Integrity signals

Registry

Crossref · 10.1016/0016-5085(92)90335-v

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Several prospective randomised placebo-controlled trials have shown rifampicin to be effective in the management of cholestatic pruritus.
“Several prospective randomised placebo-controlled trials have shown rifampicin to be effective in the management of cholestatic pruritus.182–185”
From The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines (2018) · cites this paper as [185]

A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755 · see citing works
IS URSODEOXYCHOLIC ACID AN EFFECTIVE TREATMENT FOR PRIMARY BILIARY CIRRHOSIS?
Poupon, R. Y., Poupon, R., Calmus, Y., Chrétien, Y., Ballet, F., & Darnis, F. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91610-2 · Cited by 534 · see citing works
The presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504 · see citing works
Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients
Christensen, E., Crowe, J., Doniach, D., Pópper, H., Ranek, L., Rodés, J., Tygstrup, N., & Williams, R. L. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90571-5 · Cited by 271 · see citing works
Self-citation
Treatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267 · see citing works
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257 · see citing works
COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91608-5 · Cited by 231 · see citing works
Self-citation
Relief of the Pruritus of Jaundice with a Bile-Acid Sequestering Resin
Carey, J. B. (1961) · JAMA · doi:10.1001/jama.1961.03040180034008 · Cited by 134 · see citing works
Phenobarbital Effects in Cholestatic Liver Disease
BLOOMER, J. R., & BOYER, J. L. (1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-82-3-310 · Cited by 120 · see citing works
Rifampin relieves pruritus in children with cholestatic liver disease
Cynamon, H. A., Andres, J. M., & Iafrate, R. P. (1990) · Gastroenterology · doi:10.1016/0016-5085(90)90027-x · Cited by 109 · see citing works
Treatment of pruritus due to chronic obstructive liver disease.
Duncan, J. S., Kennedy, H. J., & Triger, D. R. (1984) · BMJ · doi:10.1136/bmj.289.6436.22 · Cited by 90 · see citing works
High Incidence of Poor Sulfoxidation in Patients with Primary Biliary Cirrhosis
Olomu, A. B., VICKERS, C. R., Waring, R. H., Clements, D., Babbs, C., Warnes, T. W., & Elias, E. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804283181703 · Cited by 78 · see citing works
Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis
Hoensch, H. P., Balzer, K., Dylewizc, P., Kirch, W., Goebell, H., & Ohnhaus, E. E. (1985) · European Journal of Clinical Pharmacology · doi:10.1007/bf00544371 · Cited by 76 · see citing works
Adverse reactions to rifampicin.
Girling, D. J., & Hitze, K. L. (1979) · PubMed · Cited by 72 · see citing works
Pruritus in hepatic cholestasis. Pathogenesis and therapy
Garden, J. M. (1985) · Archives of Dermatology · doi:10.1001/archderm.121.11.1415 · Cited by 57 · see citing works
A combination of phototherapy and cholestyramine for the relief of pruritus in primary biliary cirrhosis
Cerio, R., Murphy, G. M., Sladen, G. E., & MACDONALD, D. M. (1987) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1987.tb05825.x · Cited by 52 · see citing works
Plasmaphoresis and plasma exchange in the treatment of hyperlipaemia and xanthomatous neuropathy in patients with primary biliary cirrhosis
Turnberg, L. A., Mahoney, M. P., Gleeson, M. H., Freeman, C. B., & Gowenlock, A. H. (1972) · Gut · doi:10.1136/gut.13.12.976 · Cited by 51 · see citing works
Rifampin
Farr, B. M., & Mandell, G. L. (1982) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)31449-3 · Cited by 49 · see citing works
Effect of stanozolol on itching in primary biliary cirrhosis
Walt, R. P., Daneshmend, T. K., Fellows, I. W., & Toghill, P. J. (1988) · BMJ · doi:10.1136/bmj.296.6622.607 · Cited by 41 · see citing works
Failure of Rifampin to Relieve Pruritus in Chronic Liver Disease
Woolf, G. M., & Reynolds, T. B. (1990) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199004000-00012 · Cited by 40 · see citing works
Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man
Ohnhaus, E. E., Gerber-Taras, E., & Park, B. K. (1983) · European Journal of Clinical Pharmacology · doi:10.1007/bf00613826 · Cited by 35 · see citing works
Unusual Trihydroxy Bile Acids in the Urine of Patients Treated With Chenodeoxycholate, Ursodeoxycholate or Rifampicin and Those With Cirrhosis
Nakashima, T., Sano, A., Seto, Y., Nakajima, T., Shima, T., Sakamoto, Y., Okuno, T., Kashima, K., & Hasegawa, T. (1990) · Hepatology · doi:10.1002/hep.1840110215 · Cited by 20 · see citing works
RELIEF OF THE PRURITUS OF JAUNDICE WITH METHANDROSTENOLONE AND SPECULATIONS ON THE NATURE OF PRURITUS IN LIVER DISEASE
Alva, J., & Iber, F. L. (1965) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196507000-00009 · Cited by 14 · see citing works
The relief of pruritus in primary biliary cirrhosis by hydroxyethylrutosides
Hishon, S., ROSE, J. D., & Hunter, J. O. (1981) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1981.tb00778.x · Cited by 8 · see citing works

Flagged first, then by citations

Sorted by citations

EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729 · see citing works
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480 · see citing works
Primary Biliary Cirrhosis
Schwab, M. (2011) · Springer eBooks · doi:10.1007/978-3-642-16483-5_4730 · Cited by 1,241 · see citing works
An Official ATS Statement: Hepatotoxicity of Antituberculosis Therapy
Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J., Nolan, C. M., Peloquin, C. A., Gordin, F. M., Nunes, D., Strader, D. B., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200510-1666st · Cited by 1,171 · see citing works
A Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR
Urizar, N. L., Liverman, A. D. B., Dodds, D. T., Silva, F. V., Ordentlich, P., Yan, Y. G., Gonzalez, F. J., Heyman, R. A., Mangelsdorf, D. J., & Moore, D. D. (2002) · Science · doi:10.1126/science.1072891 · Cited by 553 · see citing works
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537 · see citing works
Primary Biliary Cirrhosis
Kaplan, M. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611213352107 · Cited by 455 · see citing works
Management of primary biliary cirrhosis
Heathcote, J. (2000) · Hepatology · doi:10.1053/he.2000.5984 · Cited by 412 · see citing works
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 347 · see citing works
Risk Factors for Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., & Björnsson, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.001 · Cited by 347 · see citing works
Oral naltrexone treatment for cholestatic pruritus: A double-blind, placebo-controlled study
Wolfhagen, F., Sternieri, E., Hop, W., Vitale, G., Bertolotti, M., & Van Buuren, H. (1997) · Gastroenterology · doi:10.1053/gast.1997.v113.pm9322521 · Cited by 343 · see citing works
Role of Nuclear Receptors in the Adaptive Response to Bile Acids and Cholestasis: Pathogenetic and Therapeutic Considerations
Zollner, G., Marschall, H., Wagner, M., & Trauner, M. A. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060010s · Cited by 334 · see citing works
Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans
Marschall, H., Wagner, M., Zollner, G., Fickert, P., Diczfalusy, U., Gumhold, J., Silbert, D., Fuchsbichler, A., Benthin, L., Grundström, R., et al. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.009 · Cited by 321 · see citing works
Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration
Geier, A., Wagner, M., Dietrich, C. G., & Trauner, M. A. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.04.014 · Cited by 313 · see citing works
Primary biliary cholangitis: pathogenesis and therapeutic opportunities
Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0226-7 · Cited by 308 · see citing works
New molecular insights into the mechanisms of cholestasis.
Wagner, M., Zollner, G., & Trauner, M. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.05.012 · Cited by 270 · see citing works
Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases
Li, Y., Tang, R., Leung, P. S. C., Gershwin, M. E., & Ma, X. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.002 · Cited by 247 · see citing works
Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules
Copple, B. L., & Li, T. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.007 · Cited by 235 · see citing works
G UGULIPID : A Natural Cholesterol-Lowering Agent
Urizar, N. L., & Moore, D. D. (2003) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.23.011702.073102 · Cited by 234 · see citing works
Nuclear receptors constitutive androstane receptor and pregnane X receptor ameliorate cholestatic liver injury
Stedman, C. A. M., Liddle, C., Coulter, S., Sonoda, J., Alvarez, J. G. A., Moore, D. D., Evans, R. M., & Downes, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409794102 · Cited by 228 · see citing works
Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid
Honda, A., Ikegami, T., Nakamuta, M., Miyazaki, T., Iwamoto, J., Hirayama, T., Saito, Y., Takikawa, H., Imawari, M., & Matsuzaki, Y. (2013) · Hepatology · doi:10.1002/hep.26018 · Cited by 210 · see citing works
Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis
Prince, M. I., Burt, A. D., & Jones, D. E. J. (2002) · Gut · doi:10.1136/gut.50.3.436 · Cited by 202 · see citing works
The Pruritus of Cholestasis
Jones, A. E., & Bergasa, N. V. (1999) · Hepatology · doi:10.1002/hep.510290450 · Cited by 202 · see citing works
Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study
Terg, R., Coronel, E., Sordá, J., Muñoz, A. E., & Findor, J. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00318-5 · Cited by 199 · see citing works
Rifamycins – Obstacles and opportunities
Aristoff, P. A., Garcia, G. A., Kirchhoff, P. D., & Showalter, H. D. (2010) · Tuberculosis · doi:10.1016/j.tube.2010.02.001 · Cited by 185 · see citing works
The efficacy and safety of bile acid binding agents, opioid antagonists or rifampin in the treatment of cholestasis-associated pruritus
Tandon, P., Rowe, B. H., Vandermeer, B., & Bain, V. G. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01200.x · Cited by 176 · see citing works
Primary biliary cirrhosis
Hohenester, S. D., Elferink, R. P. J. O., & Beuers, U. H. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0164-5 · Cited by 176 · see citing works
Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials
Khurana, S., & Singh, P. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01326.x · Cited by 162 · see citing works
Primary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159 · see citing works
Nuclear receptors as therapeutic targets in cholestatic liver diseases
Zollner, G., & Trauner, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00030.x · Cited by 146 · see citing works
The pregnane X receptor: from bench to bedside
Ma, X., Idle, J. R., & Gonzalez, F. J. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.7.895 · Cited by 142 · see citing works
Natural history of pruritus in primary biliary cirrhosis
Talwalkar, J. A., Souto, E., Jorgensen, R. A., & Lindor, K. D. (2003) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(03)00134-4 · Cited by 141 · see citing works
Evolution and Function of the NR1I Nuclear Hormone Receptor Subfamily (VDR, PXR, and CAR) with Respect to Metabolism of Xenobiotics and Endogenous Compounds
Reschly, E. J., & Krasowski, M. D. (2006) · Current Drug Metabolism · doi:10.2174/138920006776873526 · Cited by 140 · see citing works
Drug‐induced cholestasis
Sundaram, V., & Björnsson, E. S. (2017) · Hepatology Communications · doi:10.1002/hep4.1088 · Cited by 138 · see citing works
Pruritus in cholestatic and other liver diseases
Mela, M. G., Mancuso, A., & Burroughs, A. K. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01458.x · Cited by 129 · see citing works
Pathogenesis and Treatment of Pruritus in Cholestasis
Kremer, A. E., Beuers, U. H., Elferink, R. P. J. O., & Pusl, T. (2008) · Drugs · doi:10.2165/00003495-200868150-00006 · Cited by 127 · see citing works
Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy
Purohit, T. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i7.926 · Cited by 118 · see citing works
Pharmacogenomics of Anti-TB Drugs-Related Hepatotoxicity
Roy, P. D., Majumder, M., & Roy, B. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.3.311 · Cited by 114 · see citing works
Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis
Pares, A., Cisneros, L., Salmeron, J. M., Caballeria, L., Mas, A., Torras, A., & Rodes, J. (2004) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.30204.x · Cited by 112 · see citing works
Self-citation
The pruritus of cholestasis
Bergasa, N. V. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.09.004 · Cited by 112 · see citing works
Chemical genomics: Functional analysis of orphan nuclear receptors in the regulation of bile acid metabolism
Willson, T. M., Jones, S. A., Moore, J. T., & Kliewer, S. A. (2001) · Medicinal Research Reviews · doi:10.1002/med.1023 · Cited by 110 · see citing works
Benign recurrent intrahepatic cholestasis
Luketic, V. A., & Shiffman, M. L. (2004) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00133-8 · Cited by 108 · see citing works
Pathophysiology and current management of pruritus in liver disease
Kremer, A. E., Elferink, R. P. J. O., & Beuers, U. H. (2011) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2010.10.007 · Cited by 106 · see citing works
Hepatoprotective effect of Ginkgoselect Phytosome® in rifampicin induced liver injurym in rats: Evidence of antioxidant activity
Suresh Ramnath, N. A. I. K., & Panda, V. S. (2008) · Fitoterapia · doi:10.1016/j.fitote.2008.02.013 · Cited by 105 · see citing works
Parenteral Nutrition‐Associated Liver Complications in Children
Btaiche, I. F., & Khalidi, N. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.3.188.33553 · Cited by 101 · see citing works
Artificial liver support in patients with liver failure: a modified DELPHI consensus of international experts
Saliba, F., Bañares, R., Larsen, F. S., Wilmer, A. P., Parés, A. R., Mitzner, S. R., Stange, J., Fuhrmann, V., Gilg, S., Hassanein, T., et al. (2022) · Intensive Care Medicine · doi:10.1007/s00134-022-06802-1 · Cited by 98 · see citing works
Self-citation
Rifampicin in the treatment of severe intrahepatic cholestasis of pregnancy
Geenes, V., Chambers, J., Khurana, R., Shemer, E. W., Sia, W., Mandair, D., Elias, E., Marschall, H.-U., Hague, W., & Williamson, C. (2015) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2015.03.020 · Cited by 98 · see citing works
Review article: the use of potentially hepatotoxic drugs in patients with liver disease
GUPTA, N. K., & Lewis, J. H. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03822.x · Cited by 96 · see citing works
Primary sclerosing cholangitis
Silveira, M. G., & Lindor, K. D. (2008) · Canadian Journal of Gastroenterology · doi:10.1155/2008/824168 · Cited by 93 · see citing works
New Insights in Genetic Cholestasis: From Molecular Mechanisms to Clinical Implications
Sticová, E., Jirsa, M., & Pawłowska, J. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/2313675 · Cited by 91 · see citing works
Unexpected Clinical Remission of Cholestasis After Rifampicin Therapy in Patients With Normal or Slightly Increased Levels of Γ-Glutamyl Transpeptidase
Cançado, E. L. R., Leitão, R. M. C., Carrilho, F. J., & Laudanna, A. A. (1998) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1998.00472.x · Cited by 89 · see citing works
Effect of oral naltrexone on pruritus in cholestatic patients
Mansour-Ghanaei, F. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i7.1125 · Cited by 89 · see citing works
Management of cholestatic disease in 2017
de Vries, E., & Beuers, U. H. (2017) · Liver International · doi:10.1111/liv.13306 · Cited by 89 · see citing works
Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity
Zollner, G., Wagner, M., & Trauner, M. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.03.005 · Cited by 89 · see citing works
Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites
Sonoda, J., Chong, L.-W., Downes, M., Barish, G. D., Coulter, S., Liddle, C., Lee, C., & Evans, R. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409481102 · Cited by 89 · see citing works
Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis
Karlsen, T. H., Vesterhus, M. N., & Boberg, K. M. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12581 · Cited by 86 · see citing works
Immunology of bile acids regulated receptors
Fiorucci, S., Marchianò, S., Urbani, G., Giorgio, C. D., Distrutti, E., Zampella, A., & Biagioli, M. (2024) · Progress in Lipid Research · doi:10.1016/j.plipres.2024.101291 · Cited by 84 · see citing works
Xenobiotic-Activated Receptors: From Transcription to Drug Metabolism to Disease
Ma, Q. (2008) · Chemical Research in Toxicology · doi:10.1021/tx800156s · Cited by 85 · see citing works
Pruritus and fatigue in primary biliary cirrhosis
Bergasa, N. V., Mehlman, J. K., & Jones, E. A. (2000) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2000.0109 · Cited by 83 · see citing works
Drug-Induced Cholestasis
Bjornsson, E. S., & Jonasson, J. G. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.11.002 · Cited by 83 · see citing works
Pathogenesis and Management of Pruritus in PBC and PSC
Kremer, A. E., Namer, B., Bolier, R., Fischer, M. J. M., Elferink, R. P. J. O., & Beuers, U. H. (2015) · Digestive Diseases · doi:10.1159/000440829 · Cited by 82 · see citing works
Advances in Pathogenesis and Management of Pruritus in Cholestasis
Kremer, A. E., Bolier, R., van Dijk, R., Elferink, R. P. J. O., & Beuers, U. H. (2014) · Digestive Diseases · doi:10.1159/000360518 · Cited by 79 · see citing works
The PXR is a drug target for chronic inflammatory liver disease
Wallace, K., Cowie, D. E., Konstantinou, D. K., Hill, S. J., Tjelle, T. E., Axon, A., Koruth, M., White, S. A., Carlsen, H., Mann, D. A., et al. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.04.012 · Cited by 77 · see citing works
Stimulation of bile acid 6α-hydroxylation by rifampin
Wietholtz, H., Marschall, H., Sjövall, J., & Matern, S. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80268-6 · Cited by 76 · see citing works
Interplay between cholesterol and drug metabolism
Režen, T., Rozman, D., Pascussi, J., & Monostory, K. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.05.014 · Cited by 75 · see citing works
Pain as a complication of use of opiate antagonists for symptom control in cholestasis
Mcrae, C. A., Prince, M. I., Hudson, M., Day, C. P., James, O. F. W., & Jones, D. E. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00879-5 · Cited by 73 · see citing works
Cholestatic Liver Disease
Gossard, A. A., & Talwalkar, J. A. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.09.002 · Cited by 72 · see citing works
The rational use of potentially hepatotoxic medications in patients with underlying liver disease
Lewis, J. H. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.2.159 · Cited by 73 · see citing works
A controlled trial of ondansetron in the pruritus of cholestasis
O’Donohue, J., Pereira, S. P., Ashdown, A. C., Haigh, C. G., Wilkinson, J., & Williams, R. L. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02430.x · Cited by 71 · see citing works
Causality assessment in drug-induced hepatotoxicity
Andrade, R. J., Camargo, R., Lucena, M. I., & González‐Grande, R. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.4.329 · Cited by 71 · see citing works
Pruritus in Chronic Cholestatic Liver Disease
Bunchorntavakul, C., & Reddy, K. R. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.03.010 · Cited by 68 · see citing works
Regulation of Transporters by Nuclear Hormone Receptors: Implications during Inflammation
Teng, S., & Piquette‐Miller, M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700102q · Cited by 68 · see citing works
Management of Primary Sclerosing Cholangitis
Lee, Y., & Kaplan, M. M. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05585.x · Cited by 65 · see citing works
Pruritus in Primary Biliary Cirrhosis: Pathogenesis and Therapy
Bergasa, N. V. (2008) · Clinics in Liver Disease · doi:10.1016/j.cld.2008.02.013 · Cited by 57 · see citing works
CHANGING INDICATIONS FOR LIVER TRANSPLANTATION
Lake, J. R. (1993) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(21)00063-7 · Cited by 57 · see citing works
Clinical application of transcriptional activators of bile salt transporters
Baghdasaryan, A., Chiba, P., & Trauner, M. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.12.001 · Cited by 56 · see citing works
Drug-induced cholestasis
Levy, C., & Lindor, K. D. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00032-1 · Cited by 56 · see citing works
Ursolic Acid, a Novel Liver X Receptor α (LXRα) Antagonist Inhibiting Ligand-Induced Nonalcoholic Fatty Liver and Drug-Induced Lipogenesis
Lin, Y.-N., Wang, C. C. N., Chang, H., Chu, F.-Y., Hsu, Y.-A., Cheng, W.-K., Ma, W.-C., Chen, C., Wan, L., & Lim, Y.-P. (2018) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.8b04116 · Cited by 54 · see citing works
Treatment of Pruritus Secondary to Liver Disease
Düll, M. M., & Kremer, A. E. (2019) · Current Gastroenterology Reports · doi:10.1007/s11894-019-0713-6 · Cited by 53 · see citing works
Intermediates of rifamycin polyketide synthase produced by an Amycolatopsis mediterranei mutant with inactivated rifF gene
Stratmann, A., Toupet, C., SCHILLING, W., Traber, R., Oberer, L., & Schupp, T. (1999) · Microbiology · doi:10.1099/00221287-145-12-3365 · Cited by 53 · see citing works
Primary Biliary Cholangitis and Primary Sclerosing Cholangitis
Yokoda, R. T., & Carey, E. J. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000268 · Cited by 51 · see citing works
Recent advances in the management of pruritus in chronic liver diseases
Tajiri, K., & Shimizu, Y. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i19.3418 · Cited by 52 · see citing works
Cholestatic pruritus: Emerging mechanisms and therapeutics
Patel, S. P., Vasavda, C., Ho, B. K., Meixiong, J., Dong, X., & Kwatra, S. G. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.04.035 · Cited by 55 · see citing works
Drug treatment of pruritus in liver diseases
Hegade, V. S., Kendrick, S. F. W., & Jones, D. E. (2015) · Clinical Medicine · doi:10.7861/clinmedicine.15-4-351 · Cited by 52 · see citing works
Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis
Silveira, M. G., & Lindor, K. D. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.873404 · Cited by 50 · see citing works
Coordinate Regulation of Drug Metabolism by Xenobiotic Nuclear Receptors: UGTs Acting Together with CYPs and Glucuronide Transporters
Bock, K. W., & Köhle, C. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-200033455 · Cited by 49 · see citing works
Pruritus and fatigue in primary biliary cirrhosis
Bergasa, N. V. (2003) · Clinics in Liver Disease · doi:10.1016/s1089-3261(03)00105-3 · Cited by 48 · see citing works
A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis
Hegade, V. S., Bolier, R., Elferink, R. P. J. O., Beuers, U. H., Kendrick, S. F. W., & Jones, D. E. (2015) · Frontline Gastroenterology · doi:10.1136/flgastro-2015-100618 · Cited by 46 · see citing works
Clinical features and management of primary biliary cirrhosis
Crosignani, A., Battezzati, P. M., Invernizzi, P., Selmi, C. F., Prina, E., & Podda, M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3313 · Cited by 46 · see citing works
Transcriptional regulation of hepatobiliary transport systems in health and disease: Implications for a rationale approach to the treatment of intrahepatic cholestasis
Wagner, M., & Trauner, M. A. (2005) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32071-x · Cited by 46 · see citing works
PRIMARY BILIARY CIRRHOSIS AND PRIMARY SCLEROSING CHOLANGITIS
Angulo, P., & Lindor, K. D. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70084-2 · Cited by 46 · see citing works
Antimicrobial agents for the dermatologist. II. Macrolides, fluoroquinolones, rifamycins, tetracyclines, trimethoprim-sulfamethoxazole, and clindamycin
Epstein, M. E., Amodio-Groton, M. I., & Sadick, N. S. (1997) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(18)30730-8 · Cited by 46 · see citing works
Nuclear Receptors CAR and PXR; therapeutic targets for cholestatic liver disease
Kakizaki, S. (2011) · Frontiers in bioscience · doi:10.2741/3893 · Cited by 44 · see citing works
No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis
Dilger, K., Denk, A., Heeg, M. H. J., & Beuers, U. H. (2005) · Hepatology · doi:10.1002/hep.20568 · Cited by 43 · see citing works
Extrahepatic manifestations of cholestasis
Glasová, H., & Beuers, U. H. (2002) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2002.02717.x · Cited by 43 · see citing works
Nuclear receptors in the cross-talk of drug metabolism and inflammation
Gerbal‐Chaloin, S., Iankova, I., Maurel, P., & Daujat‐Chavanieu, M. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2012.756011 · Cited by 41 · see citing works
Evaluation and Management of Pruritus in Primary Biliary Cholangitis
Düll, M. M., & Kremer, A. E. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.009 · Cited by 41 · see citing works
Role of N-acetylcysteine in rifampicin-induced hepatic injury of young rats
Rana, S., Attri, S. V., Vaiphei, K., Pal, R., Attri, A., & Singh, K. (2006) · World Journal of Gastroenterology · doi:10.3748/wjg.v12.i2.287 · Cited by 40 · see citing works
Medical and Nutritional Management of Cholestasis in Infants and Children
Feranchak, A. P., & Sokol, R. J. (2007) · Cambridge University Press eBooks · doi:10.1017/cbo9780511547409.012 · Cited by 40 · see citing works
Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross‐disease cohort study
Webb, G. J., Rahman, S. R., Levy, C., & Hirschfield, G. M. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14579 · Cited by 39 · see citing works

Treatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267 · see citing works
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257 · see citing works
[The treatment of primary biliary liver cirrhosis with rifampicin].
Loginov, A. S., Reshetniak, V. I., & Petrakov, A. V. (1993) · PubMed · Cited by 9 · see citing works
Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis
Hoensch, H. P., Balzer, K., Dylewizc, P., Kirch, W., Goebell, H., & Ohnhaus, E. E. (1985) · European Journal of Clinical Pharmacology · doi:10.1007/bf00544371 · Cited by 76 · see citing works
COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS
Bachs, L., Elena, M., Parés, A., Piera, C., & Rodés, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91608-5 · Cited by 231 · see citing works
Self-citation

Authors: Bachs, L., Parés, A., Elena, M., Piera, C., & Rodés, J.
Affiliations: Hospital Clínic de Barcelona (ES)
ORCID: Parés, Albert
Venue: Gastroenterology
Publisher: Elsevier BV
Published: 1992-06
Volume: 102
Issue: 6
Pages: 2077-2080
ISSN: 0016-5085 (ISSN-L)
DOI: 10.1016/0016-5085(92)90335-v
OpenAlex: W1219313770
Cited by: 235
References: 24
Citations by year: 2026: 4 · 2025: 3 · 2024: 8 · 2023: 5 · 2022: 7 · 2021: 5 · 2020: 6 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 7 · 2015: 12 · 2014: 8 · 2013: 5 · 2012: 7
FWCI: 1.83
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Keywords: rifampicin, primary biliary cirrhosis, pruritus, cholestasis, drug-induced hepatitis, aminopyrine breath test, alkaline phosphatase, bile acids, long-term drug therapy, adverse drug reactions
MeSH terms: Bile Acids and Salts, Cholestasis, Female, Humans, Liver, Liver Cirrhosis, Biliary, Middle Aged, Pruritus, Rifampin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of long-term rifampicin administration in primary biliary cirrhosis

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks